

BEST AVAILABLE COPY

UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT FORM PTO-1449

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

Attorney Docket No.
Serial No.
Applicant
Filing Date
Group
IDS Filed
Customer No.

Sheet 1 of 1
50059/005002
09/762,577
Glenn Dranoff et al.
February 7, 2001
Not Yet Assigned
March 7, 2001
21559

TRADEMARK OFFICE
173
301

U.S. PATENTS

Patentee

Class

Subclass

Filing Date
(If Appropriate)

OR PUBLISHED FOREIGN PATENT APPLICATION

Country or
Patent Office

Class

Subclass

Translation
(Yes/No)

APPROVED

Examiner's
Initials

Document
Number

Date

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

MD

Dranoff et al., "Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity," Proc. Natl. Acad. Sci. U.S.A. 90:3539-3543, 1993.

Dranoff et al., "A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor," Human Gene Therapy 7:111-123, 1997.

Ellem et al., "A case report: Immune responses and clinical course of the first human use of granulocyte-macrophage colony-stimulating factor-transduced autologous melanoma cells for immunotherapy," Cancer Immunol. Immunother. 44:10-20, 1997.

Jäger et al., "Strategies for the development of vaccines to treat breast cancer," Recent Results Cancer Res. (Germany) 152:94-102, 1998.

Scanlan et al., "Characterization of human colon cancer antigens recognized by autologous antibodies," Int. J. Cancer 76:652-658, 1998.

Simons et al., "Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer," Cancer Research 57:1537-1546, 1997.

Soffer et al., "Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma," Proc. Natl. Acad. Sci. U.S.A. 95:13141-13146, 1998.

Takahashi et al., "707-AP peptide recognized by human antibody induces human leukocyte antigen A2-restricted cytotoxic T lymphocyte killing of melanoma," Clin. Cancer Res. 3:1363-1370, 1997.

Genbank Accession No. AI459806, Hillier et al., WashU-NCI human EST Project, March 9, 1999.

Genbank Accession No. AI590782, NCI-CGAP <http://www.ncbi.nih.gov/ncicgap>, National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index, May 14, 1999.

Genbank Accession No. AI115047, Marra et al., The WashU-HHMI Mouse EST Project, September 2, 1998.

DATE CONSIDERED

EXAMINER

EXAMINER: Initial citation considered. Draw line through citation if not considered. Include copy of this form with the next communication to applicant.

/Min Tan Davis/ (05/11/2006)